WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Google wants judge, not jury, decide upcoming antitrust case in VirginiaKosovo makes lastYankees get careerHow Anya TaylorChina unveils plan to galvanize NEV uptake in rural areasWembanyama headlines France's preliminary roster for Paris Olympics basketball tournamentRylan Clark gets playful as he details intimate hotel moment with Rob Rinder during cosy interviewMore trouble in Belgium for MiamiSexual assaults are down in the US military. Here's what to knowWalmart, Canada Goose rise; Deere, Freeport